Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 45% ± 19% | |
oligodendrocyte | 10 studies | 26% ± 7% | |
platelet | 5 studies | 22% ± 5% | |
vein endothelial cell | 3 studies | 40% ± 32% | |
endothelial cell of vascular tree | 3 studies | 37% ± 23% | |
GABAergic neuron | 3 studies | 36% ± 8% | |
glutamatergic neuron | 3 studies | 45% ± 6% | |
megakaryocyte | 3 studies | 46% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 30% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 1374.57 | 89 / 89 | 97% | 53.99 | 872 / 901 |
prostate | 96% | 1299.40 | 234 / 245 | 100% | 69.87 | 501 / 502 |
pancreas | 98% | 718.68 | 320 / 328 | 89% | 13.21 | 159 / 178 |
thymus | 100% | 1488.68 | 652 / 653 | 85% | 28.71 | 517 / 605 |
brain | 100% | 1962.09 | 2630 / 2642 | 77% | 8.68 | 541 / 705 |
esophagus | 82% | 533.24 | 1188 / 1445 | 87% | 15.51 | 160 / 183 |
stomach | 75% | 388.61 | 271 / 359 | 87% | 16.29 | 249 / 286 |
intestine | 72% | 739.89 | 694 / 966 | 88% | 16.06 | 464 / 527 |
breast | 97% | 1394.71 | 446 / 459 | 59% | 7.85 | 663 / 1118 |
bladder | 76% | 394.00 | 16 / 21 | 70% | 10.31 | 353 / 504 |
lung | 72% | 389.62 | 414 / 578 | 69% | 9.21 | 802 / 1155 |
uterus | 64% | 417.99 | 109 / 170 | 66% | 8.54 | 305 / 459 |
adrenal gland | 58% | 332.00 | 149 / 258 | 48% | 6.52 | 110 / 230 |
skin | 72% | 2975.64 | 1305 / 1809 | 27% | 3.17 | 126 / 472 |
adipose | 94% | 1513.71 | 1132 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 73% | 11.07 | 33 / 45 |
ovary | 6% | 44.83 | 10 / 180 | 62% | 6.28 | 266 / 430 |
liver | 1% | 7.73 | 3 / 226 | 36% | 10.21 | 146 / 406 |
blood vessel | 34% | 226.35 | 450 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 21% | 3.17 | 6 / 29 |
peripheral blood | 10% | 45.47 | 90 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 6% | 0.46 | 5 / 80 |
heart | 3% | 16.34 | 22 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 9.23 | 16 / 803 | 0% | 0 | 0 / 0 |
spleen | 1% | 2.63 | 2 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0034626 | Biological process | fatty acid elongation, polyunsaturated fatty acid |
GO_0019367 | Biological process | fatty acid elongation, saturated fatty acid |
GO_0034625 | Biological process | fatty acid elongation, monounsaturated fatty acid |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005515 | Molecular function | protein binding |
GO_0009922 | Molecular function | fatty acid elongase activity |
Gene name | ELOVL7 |
Protein name | Very long chain fatty acid elongase 7 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL7) (ELOVL fatty acid elongase 7) (ELOVL FA elongase 7) (Elongation of very long chain fatty acids protein 7) (Very long chain 3-ketoacyl-CoA synthase 7) (Very long chain 3-oxoacyl-CoA synthase 7) ELOVL fatty acid elongase 7 Elongation of very long chain fatty acids protein (EC 2.3.1.199) (Very-long-chain 3-oxoacyl-CoA synthase) |
Synonyms | |
Description | FUNCTION: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme with higher activity toward C18 acyl-CoAs, especially C18:3(n-3) acyl-CoAs and C18:3(n-6)-CoAs. Also active toward C20:4-, C18:0-, C18:1-, C18:2- and C16:0-CoAs, and weakly toward C20:0-CoA. Little or no activity toward C22:0-, C24:0-, or C26:0-CoAs. May participate in the production of saturated and polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . |
Accessions | ENST00000425382.5 D6RBM2 D6RBR5 ENST00000511799.5 D6RE10 ENST00000508821.6 ENST00000505959.5 ENST00000514809.1 ENST00000507047.5 D6RHD0 ENST00000504455.5 A1L3X0 |